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Abstract
5-Aza-29-deoxycytidine, approved by the FDA for the treatment of myelodysplastic syndrome (MDS), is incorporated into
the DNA of dividing cells where it specifically inhibits DNA methylation by forming covalent complexes with the DNA
methyltransferases (DNMTs). In an effort to study the correlations between DNA methylation, nucleosome remodeling, and
gene reactivation, we investigate the integrated epigenetic events that worked coordinately to reprogram the methylated
and closed promoters back to permissive chromatin configurations after 5-Aza-29-deoxycytidine treatment. The ChIP results
indicate that H2A.Z is deposited at promoter regions by the Snf2-related CBP activator protein (SRCAP) complex following
DNA demethylation. According to our genome-wide expression and DNA methylation profiles, we find that the complete
re-activation of silenced genes requires the insertion of the histone variant H2A.Z, which facilitates the acquisition of regions
fully depleted of nucleosome as demonstrated by NOMe–seq (Nucleosome Occupancy Methylome–sequencing) assay. In
contrast, SRCAP–mediated H2A.Z deposition is not required for maintaining the active status of constitutively expressed
genes. By combining Hpa II digestion with NOMe–seq assay, we show that hemimethylated DNA, which is generated
following drug incorporation, remains occupied by nucleosomes. Our data highlight H2A.Z as a novel and essential factor
involved in 5-Aza-29-deoxycytidine–induced gene reactivation. Furthermore, we elucidate that chromatin remodeling
translates the demethylation ability of DNMT inhibitors to their downstream efficacies, suggesting future therapeutic
implications for chromatin remodelers.
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Introduction
The eukaryotic genome is compacted into chromatin and
associated proteins. The fundamental repeating unit of chromatin
is the nucleosome, which contains ,147 bp of DNA wrapped
around a histone protein octamer [1]. However, chromatin
conformations change during various cellular processes, such as
the cell cycle, transcription or DNA damage [2]. During gene
activation, transcription factors compete with chromatin packag-
ing proteins in order to gain access to the DNA sequence and read
the genetic information accurately. Accumulated evidence shows
that the chromatin architecture of gene promoter regions strongly
regulates gene transcription [3]. This chromatin environment
might be altered by DNA methylation, post-translational modifi-
cations of histone proteins, histone variants and nucleosome
positioning [4].
In mammalian cells, ,60% of gene promoters are located
within CpG islands, where cytosine methylation of CpG
dinucleotides impairs gene expression. Histone modifications and
histone variants are also strongly correlated with transcriptional
status [3]. Nucleosome positioning plays an essential role in gene
transcriptional regulation according to recent genome wide
studies, which show that the majority of active or poised promoters
have decreased nucleosome density [5]. Furthermore, the histone
variants H2A.Z and H3.3, which are located at specific genome
regions such as promoters, enhancers and insulators, work
coordinately to destabilize nucleosomes [6–8]. The ATP depen-
dent nucleosome remodelers catalyzing H2A.Z incorporation,
namely SRCAP and p400 complexes in mammalian cells, have
been suggested to be involved in transcriptional regulation,
however, the role of H2A.Z remains controversial [9–15].
Abnormalities in epigenetic modifications play an essential role
in tumorigenesis [16], and the reversal of them is the basic concept
of epigenetic therapy for cancer. DNA methyltransferases (DNMT
inhibitors), such as 5-azacytidine (5-Aza-CR) and 5-Aza-29-
deoxycytidine (5-Aza-CdR), are approved by the FDA for the
treatment of MDS [17–18]. Although CpG demethylation is the
direct and immediate consequence of treatment with DNMT
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ylation in tumor suppressor genes does not predict clinical
outcome, which suggests that unknown biological processes link
the demethylation effects of DNMT inhibitors to their clinical
benefits [20]. Several reports have already shown that, in addition
to CpG demethylation, DNMT inhibitors indirectly reduce some
repressive histone marks, increase acetylation of histone H3 and
promote nucleosome depletion upstream of the transcription start
sites (TSS) [21–24].
Here, taking advantage of a high resolution nucleosome
positioning assay developed by our laboratory, we further study
the integrated epigenetic changes following 5-Aza-CdR induced
demethylation. In addition to the rapid enrichment of H3K4me3
at promoter regions, we find that H2A.Z incorporation increases
in response to demethylation. Notably, CpG demethylation
induced enrichment of H2A.Z and H3K4me3, as well as
nucleosome depletion coordinately constitute a ‘‘permissive’’
chromatin architecture independently of histone acetylation levels.
Inhibiting H2A.Z deposition by SRCAP knockdown lessens the
establishment of ‘‘permissive’’ promoter environments and
ultimately reduces the levels of gene reactivation after 5-Aza-
CdR treatment. Genome-wide gene expression and DNA
methylation studies further confirm that SRCAP-mediated
H2A.Z insertion promotes DNA demethylation induced gene re-
expression but has minimal effects on constitutively active genes.
Our study reveals an important function of SRCAP/H2A.Z in
promoting the reactivation process induced by 5-Aza-CdR but not
in maintaining the expression of constitutively active genes and
provides an insight to the chromatin structure of hemimethylated
DNA.
Results
5-Aza-CdR induces activation of methylation silenced
genes by demethylating DNA and changing chromatin
structure around promoter regions
To investigate the effects of DNA demethylation on chromatin
architecture and gene expression, we treated the RKO colon
cancer cell line, with 1 uM 5-Aza-CdR for 24 hours and followed
the sequential changes in mRNA expression, DNA methylation
and histone marks at the promoters of the MLH1, CDKN2A and
MYOD1, which are methylated and silenced in RKO cells
(Figure 1).
MLH1 expression began to rise at D2 after 5-Aza-CdR
treatment, reaching a maximal level at D3 and remained constant
for 4 days (Figure 1A). We performed a quantitative Methylation-
sensitive Single-Nuleotide Primer Extension (Ms-SNuPE) assay to
detect the DNA methylation changes at the indicated days
(Figure 1B). A striking decrease in DNA methylation was observed
at D2 (,40%). The methylation level at the MLH1 promoter
remained nearly constant from D2 to D9. We then used ChIP to
monitor the changes of histone marks after 5-Aza-CdR treatment
(Figure 1C). The enrichments of H2A.Z, H3K4me3 and H3K9/
14 acetylation (acH3K9/14) were normalized to histone H3 levels
to eliminate the potential influence of nucleosome depletion after
drug treatment, and the ChIP primers were designed to amplify
stable nucleosome regions which located just downstream of TSSs
[5]. Interestingly, our results showed that the H2A.Z enrichment
significantly changed after 5-Aza-CdR treatment (p,0.001), and
could be observed as early as D2 when DNA methylation was
substantially decreased (Figure 1C). H3K4me3 increased imme-
diately after treatment and the enrichment of acH3K9/14
modestly increased at D2 and peaked by D3 displaying a similar
pattern to the levels of MLH1 expression (Figure 1A).
The mRNA levels of CDKN2A rose steadily from D2 after 5-
Aza-CdR treatment and peaked at D7 but abruptly dropped at D9
(Figure 1D). Although the active histone marks increased at the
promoter of CDKN2A in a manner similar to MLH1, the H2A.Z
level (p,0.05) diminished nearly to the baseline at D9 along with a
rapid decline of acH3K9/14 from D5 to D9 (Figure 1F).
The mRNA level of MYOD1, a self-regulated gene expressed
exclusively in muscle cells, remained undetectable and showed no
RNA polymerase II (pol II) enrichment after 5-Aza-CdR
treatment even though it showed a demethylation pattern similar
to that of MLH1 (Figure 1G, 1H; Figure S1A). Most interestingly,
we observed modest changes in H2A.Z and H3K4me3 at the
MYOD1 promoter, whereas acH3K9/14 remained extremely low,
in agreement with its low expression level (Figure 1I). Therefore
the MYOD1 promoter acquired a ‘‘permissive’’ state for expression
after 5-Aza-CdR treatment but the gene was not expressed.
In addition to analyzing DNA methylation changes at the single
strand level (Figure 1B, 1E, 1H), we detected and quantified
asymmetrically methylated DNA after 5-Aza-CdR treatment. We
performed a hemimethylation Ms-SNuPE assay based on Hpa II
digestion as we have developed previously and used the CDKN2A
gene as a model (Figure S1B-S1D) [25]. The majority of DNA
molecules were hemimethylated DNA duplexes at D2 (,60%).
Even at D5, ,5% of the DNA duplexes were composed of
hemimethylated DNA molecules. There was a small portion of
fully demethylated DNA duplexes at D2, however, the maximal
levels of double strand demethylation (,40%) was detected at D3–
5 when hemimethylated DNA levels dropped.
Collectively, our results demonstrate that 5-Aza-CdR treatment
eventually produces two types of demethylated DNA duplexes,
hemimethylated and fully demethylated DNA. After demethyla-
tion H2A.Z and H3K4me3 are deposited in all three promoters.
Interestingly, only acH3K9/14 shows a correlation between its
enrichment and mRNA expression.
Nucleosome occupancy is disrupted by 5-Aza-CdR
treatment
We next investigated the effects of 5-Aza-CdR on nucleosome
occupancy (Figure 2, Figure 3). We previously examined the
nucleosome occupancy status of the MLH1 promoter in RKO and
LD419 cells using MNase-ChIP assay and Methylase-based
Author Summary
Epigenetic changes, which include chemical modifications
to the DNA and changes in the proteins that package DNA
to fit into a cell, play an important role in gene expression
regulation. The fact that a number of abnormal epigenetic
changes that lead to the silencing of genes occur during
tumorigenesis has prompted the design of epigenetic
therapies. The ultimate goal of these therapies is to reverse
the aberrant epigenetic modifications observed in cancer
cells, thereby restoring cells to a ‘‘normal’’ state. 5-Aza-
CdDR, a FDA approved drug for MDS treatment, reverses a
chemical modification of the DNA resulting in gene
reactivation. The data presented here show the impor-
tance of H2A.Z, a special DNA packaging protein variant, in
the gene reactivation process induced by 5-Aza-CdR. The
presence of H2A.Z facilitates the access of proteins at gene
regulatory regions, which is a necessary step for gene re-
expression. A better understanding of the events that
follow 5-Aza-CdR treatment is a necessary step towards
the design of combination and/or personalized epigenetic
therapies.
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previous findings using a recently developed high resolution assay,
which uses the GpC methyltransferase (M.CviPI) instead of CpG
methyltransferase (M.SssI) to methylate GpC sites that are not
occupied by nucleosomes or tightly bound transcription factors
[26]. By analyzing the methylation status of GpC sites, this
NOMe-seq (Nucleosome Occupancy Methylome-sequencing)
assay provides a digital footprint of nucleosome occupancy and
allows the study of nucleosome positioning in both CpG islands
and CpG poor regions regardless of their CpG methylation status.
Nucleosome occupancy at the MLH1 and CDKN2A promoters
in LD419 and RKO cells were analyzed by NOMe-seq using PCR
primers lacking CpG or GpC sites to avoid complications due to
cytosine methylation in the parental molecules (Figure 2). Both
promoters were unmethylated in LD419 cells and had clear
nucleosome depleted regions (NDRs) which were accessible to the
exogenous M.CviPI. In contrast, the promoters of MLH1 and
CDKN2A were methylated in RKO cells and were inaccessible to
the GpC methyltransferase, indicating that hypermethylated
promoters were fully occupied by nucleosomes.
To investigate the nucleosome occupancy changes accompany-
ing drug induced DNA demethylation, we used primers which
were specifically designed to amplify the DNA strands which had
become demethylated at CpG sites and studied the accessibility of
these demethylated molecules to M.CviPI (Figure 3; Figure S2).
The maximum demethylation of CpG sites was observed at D2
(Figure 1B), but only one out of twenty-five demethylated DNA
strands (4%) had a nucleosome depleted region larger than 146 bp
around the TSS (green bar on the graph)(Figure 3A). At D3, a
proportion of unmethylated DNA strands at the gene promoters
(24%) showed a nucleosome depleted area large enough to
accommodate at least one nucleosome, consistent with the
presence of active histone marks and increased gene expression.
Extensive nucleosome depletion (40%), the H2A.Z enrichment
and gene reactivation reached a maximal level at D5 (Figure 3A).
NOMe-seq analysis of the CDKN2A promoter yielded similar
Figure 1. 5-Aza-CdR induces dynamic changes in gene expression, DNA methylation, and histone marks. A, D, G, RT-PCR results
showing the expression levels of MLH1, CDKN2A and MYOD1 at the indicated days (D) after 1 uM 5-Aza-CdR treatment. The mRNA levels were
normalized to GAPDH. Error bars represent the standard deviation of biological triplicates. B, E, H, DNA methylation levels at promoters were
measured by Ms-SNuPE. Error bars represent the range between biological duplicates. C, F, I, ChIP results of histone variants and modifications were
normalized to histone H3 at the indicated time points after treatment. Arrows indicate TSSs and the upper vertical bars represent CpG sites.
Underlying bold horizontal lines indicate the ChIP regions amplified by PCR. Results from three independent biological experiments of H2A.Z and two
independent biological experiments of H3K4me3 (acH3K9/14) are shown.
doi:10.1371/journal.pgen.1002604.g001
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(Figure 3B). Interestingly, the MYOD1 promoter showed drug-
induced enrichment of H2A.Z and H3K4me3 as well as
nucleosome depletion around the TSS (20%) without MYOD1
expression (Figure 3C). Therefore, changes in histone modifica-
tions and nucleosome depletion were the direct consequences of
DNA demethylation and did not require transcriptional activation
for some genes, such as MYOD1.
Although the nucleosome occupancy at the MLH1 promoter
was dramatically decreased on the demethylated DNA strands at
D5 after 5-Aza-CdR treatment, a portion of demethylated DNA
strands remained inaccessible to M.CviPI (Figure 3A). As shown
in Figure S1C, the majority of demethylated DNA strands were
associated with hemimethylated DNA duplexes at D2. And the
demethylated DNA strands at the D2 were highly occupied by
nucleosomes. To further investigate the nucleosome occupancy
on hemimethylated DNA, we pre-digested the NOMe-seq DNA
samples before bisulfite treatment with an excess of Hpa II.
Demethylated DNA strands associated with symmetrically
demethylated DNA duplexes are destroyed by Hpa II digestion,
whereas the demethylated strands in hemimethylated DNA
duplexes are resistant to digestion (Figure S1B). Next, we used
the same PCR primers as shown previously to amplify the
remaining demethylated DNA strands. The NOMe-seq results
from Hpa II digested DNA clearly showed that the promoters of
MLH1 and CDKN2A were occupied by nucleosomes when the
underlying DNA was hemimethylated (Figure 3D, 3E). Our
results show that DNA demethylation at promoter regions
induces substantial changes in nucleosome occupancy which
only occurs on symmetrically demethylated but not hemimethy-
lated DNA.
SRCAP–mediated H2A.Z incorporation promotes
demethylation induced gene expression and
nucleosome depletion
The enrichment of H3K4me3 after demethylation has been
well studied [27], however the role of H2A.Z insertion in gene
reactivation is unclear. Thus, we explored the potential role of
H2A.Z in 5-Aza-CdR induced gene reactivation by knocking
down SRCAP (Figure S3A), which catalyzed H2A.Z deposition in
a cell cycle independent manner [28], and subsequently treating
the cells with 5-Aza-CdR (Figure 4A).
The expression of MLH1 and CDKN2A was strongly attenuated
by SRCAP knockdown, concomitant with a reduction of H2A.Z
levels at the promoters (Figure 4A). The enrichment of acH3K9/
14 at the reactivated promoters was reduced after SRCAP
knockdown as well. Interestingly, the 5-Aza-CdR induced
H2A.Z deposition was also inhibited by SRCAP knockdown at
the MYOD1 promoter, but the gene expression and acH3K9/14
levels remained undetectable as expected. Of note, SRCAP
knockdown showed minimal effects on the H3K4me3 levels at all
three promoters, suggesting that the H3K4me3 mark was
independent of H2A.Z levels. In addition, knockdown of SRCAP
did not affect DNA methylation levels at promoters of these
examined genes (Figure S3B).
In contrast, the mRNA level of GRP78, which is usually over-
expressed in cancer cells and has enriched H2A.Z around its
promoter [2], was not reduced and even modestly increased after
SRCAP knockdown. The H2A.Z level at the GRP78 promoter
dramatically dropped by nearly 90% compared with non-target
(NC) siRNA treated cells. Meanwhile, the levels of H3K4me3
and acH3K9/14 remained high showing that these marks were
independent of H2A.Z levels. In addition to GRP78, we analyzed
two more genes, LAMB3 and G3BP, both of which were
unmethylated and expressed in RKO cells (Figure S3D, S3E).
The enrichment of H2A.Z, which has been identified at both
promoters [10,29], was reduced by SRCAP knockdown, but
neither the mRNA expression nor the histone marks were
significantly affected. Remarkably, knockdown of SRCAP in
LD419 cells did not inhibit the expression of MLH1 and
CDKN2A, though the H2A.Z enrichment at the promoter regions
had been reduced. Again, no difference in H3K4me3 and
acH3K9/14 levels was detected after SRCAP siRNA treatment
(Figure S4A).
We next investigated the function of SRCAP-mediated H2A.Z
deposition on 5-Aza-CdR induced nucleosome occupancy chang-
es. Substantial nucleosome depletion at the MLH1 promoter was
observed on the demethylated DNA strands in the NC siRNA
treated cells as previously shown (Figure 4B). When SRCAP-
mediated H2A.Z incorporation was inhibited, nucleosome deple-
tion was much curtailed at the promoter (32% to 20%). Similarly,
we observed that inhibiting SRCAP-mediated H2A.Z deposition
prevented the depletion of nucleosome induced by the 5-Aza-CdR
in the vicinity of the CDKN2A (20% to 4% ) and MYOD1 (16% to
8%) TSSs. In contrast, the NDRs at the GRP78, LAMB3 and G3BP
promoters were not reduced and even showed modest increases
(Figure S3C, S3F, and S3G). Similarly, the NDRs upstream of the
TSS of MLH1 did not change after SRCAP knockdown in LD419
cells (Figure S4B).
Taken together, these results demonstrate that SRCAP-
mediated H2A.Z deposition and associated nucleosome depletion
play a key role in re-constructing a poised chromatin architecture
around demethylated promoters. In contrast, continued H2A.Z
presence is not critical in maintaining an open chromatin
environment of actively transcribed genes.
Figure 2. DNA methylation influences nucleosome occupancy.
A. Nucleosome occupancy and DNA CpG methylation levels at the
MLH1 promoter in LD419 cells (upper) and RKO cells (lower) were
investigated by NOMe-seq. B. Nucleosome occupancy and DNA CpG
methylation levels at the CDKN2A promoter in LD419 cells (upper) and
RKO cells (lower) were examined by NOMe-seq. The upper vertical bars
represent CpG sites and the lower vertical bars indicate GpC sites. Open
and filled circles represent unmethylated and methylated CpG sites
respectively. The teal filled circles indicate GpC sites which are
methylated and therefore accessible to GpC methyltransferase. Pink
areas represent regions which are resistant to GpC methyltransferase
and longer than 146 bp.
doi:10.1371/journal.pgen.1002604.g002
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Aza-CdR–activated genes but has minimal effects on
DNA methylation patterns
To elucidate the importance of H2A.Z deposition for gene
reactivation following 5-Aza-CdR induced demethylation, we
conducted genome-wide studies to assay global DNA methylation
and gene expression changes after drug treatment.
We interrogated global promoter DNA methylation patterns
using the Infinium HumanMethylation27 platform, which in-
cludes 27,578 CpG dinucleotides spanning 14,495 well-annotated,
unique gene promoter and/or 59 gene regions (from 21,500 to
+1,500 from the TSS). The DNA methylation level for each
interrogated CpG site is reported as a beta value, ranging from
zero (low DNA methylation) to one (high DNA methylation). In
NC siRNA treated cells, the CpG sites could be roughly separated
into two groups based on the bimodal distribution of the beta
values: a hypomethylated group (beta value,0.2) and a hyper-
methylated group (beta value.0.8) [30] (Figure 5A). Consistent
with the Ms-SNuPE results (Figure 1B, 1E, 1H), the CpG sites
within the promoters of MLH1, CDKN2A and MYOD1 had beta
values higher than 0.8. The peak representing hypermethylated
probes was notably shifted towards the left after 5-Aza-CdR
treatment. To further expand this observation, CpG probes were
plotted between 5-Aza-CdR and PBS treatment (control) in NC
siRNA treated cells (Figure 5B). Using a beta value difference of
0.25 as a threshold for differential DNA methylation and
separating CpG probes based on beta values.0.8 associated with
control treatment, 2,638 CpG probes (1278 genes) were identified
to be demethylated by 5-Aza-CdR in NC siRNA treated cells and
knockdown of SRCAP only showed little effect on DNA
Figure 3. Dynamic nucleosome occupancy changes on symmetrically and asymmetrically methylated DNA duplexes after 5-Aza-
CdR treatment. A. The nucleosome occupancy changes at the MLH1 promoter after 5-Aza-CdR treatment were investigated by NOMe-seq assay.
The GpC methyltransferase accessibility on each strand is shown. B. Nucleosome depleted regions were detected at the CDKN2A promoter five days
after 5-Aza-CdR treatment. C. Nucleosome depleted regions were also detected in the MYOD1 promoter five days after 5-Aza-CdR treatment. D,E. The
nucleosome occupancy on asymmetrically methylated DNA duplexes was analysis by NOMe-seq after Hpa II digestion at the MLH1 and CDKN2A
promoters. Green bars presents regions of 250 bp in length, which covers the 21 nucleosome plus 100 bp downstream of that nucleosome.
doi:10.1371/journal.pgen.1002604.g003
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PLoS Genetics | www.plosgenetics.org 5 March 2012 | Volume 8 | Issue 3 | e1002604Figure 4. SRCAP knockdown prevents 5-Aza-CdR–induced H2A.Z deposition and nucleosome remodeling. A, RKO cells were treated
with the indicated siRNA for 24 hours followed by treatment of 1 uM 5-Aza-CdR (+) or PBS (2) for another 24 hours. RNA was isolated 72 hours after
drug treatment. The gene expression levels were measured by RT-PCR and the data represent the means of biological triplicates. The enrichment of
histone marks after the indicated treatment was measured by ChIP and normalized to the Histone H3 level. The data represent biological duplicates.
B. NOMe-seq results show the nucleosome occupancy at the MLH1, CDKN2A and MYOD1 promoter after the indicated treatment.
doi:10.1371/journal.pgen.1002604.g004
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found to be demethylated in SRCAP siRNA treated cells
(Figure 5C; Figure S5A, S5B).
To evaluate gene expression changes, we performed a
permutation analysis (1,000 permutations) using Significance
Analysis of Microarrays (SAM) in NC or SRCAP siRNA
transfected cells after 5-Aza-CdR treatment [31]. The identifica-
tion of differentially expressed genes was performed among the
indicated groups (Figure 5D–5F; Figure S5C, S5D). We found that
SRCAP knockdown had minimal impact on global gene
expression (Figure 5E), while 5-Aza-CdR treatment significantly
up-regulated 97 genes (representing 130 different transcripts) in
NC treated cells and 86 genes (representing 105 different
transcripts) in SRCAP siRNA treated cells, with an 81% overlap
between two groups (Figure 5D; Figure S5E, S5F). We did not
observe any gene significantly down-regulated by 5-Aza-CdR
treatment in either NC or SRCAP siRNA treated cells.
To visualize the global gene expression difference between
SRCAP and NC siRNA, we plotted the observed log2 fold change
for all the interrogated transcripts on the platform (Figure 5F).
After extracting the promoter DNA methylation beta values of 97
genes, which were reactivated by 5-Aza-CdR in NC siRNA
treated cells from the Infinium array, we found that 44 genes
(representing 92 different CpG loci), including MLH1 and
Figure 5. DNA methylation and gene expression changes globally after 5-Aza-CdR treatment and SRCAP knockdown. A. Density plots
for each sample across all 27,578 CpG sites analyzed. The X-axis represents beta values ranging from 0 (no DNA methylation) to 1 (high DNA
methylation). Black colored lines represent samples treated with PBS and red lines are samples treated with 5-Aza-CdR. Solid lines are NC siRNA
treated samples and dashed lines are SRCAP siRNA treated samples. B,C. Scatter plot overlayed with histogram and density distribution. Each dot
represents an interrogated CpG probes beta value. Colored dots represents density or number of probes as indicated in the adjacent axis as
illustrated as a both a histogram and density distribution. Contour lines are drawn to further illustrate the number of probes for a specified region. B.
Represents a scatter plot between 5-Aza-CdR vs PBS treatment (control) in NC siRNA treated RKO cells. C. Represents a scatter plot between SRCAP
siRNA vs NC siRNA treated cells. D,E . The gene expression log2 fold difference is plotted on the x-axis, and the q-value which accesses significance is
plotted on the y-axis (21* log10 scale). Probes that are identified as significantly different between two groups are colored in red. D. NC 5-Aza-CdR vs
NC PBS; E. NC vs SRCAP siRNA F. Scatter plot of all transcript probes assayed on the Illumina Human expression beadchip. Probes identified as
differentially expressed and demethylated after 5-Aza-CdR treatment in non-target siRNA treated cells (x-axis) are colored red. Inset shows the
distribution (box plots) of the demethylation induced gene reactivation fold changes in non-target siRNA and SRCAP siRNA treated cells. G. One-
dimensional hierarchical clustering of the demethylated CpG probes which interrogate the promoters of genes significantly upregulated by 5-Aza-
CdR treatment. Each row represents a probe; each column represents a sample. The level of DNA methylation (beta value) for each probe in each
sample is represented by using the color scale shown in the legend; white indicates missing data. H. Box plot of DNA methylation levels distribution
for genes which were significantly upregulated and demethylated by 5-Aza-CdR.
doi:10.1371/journal.pgen.1002604.g005
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the heatmap and box plot (Figure 5G, 5H). We next concentrated
on these 44 genes which were demethylated and subsequently
reactivated. Within this group of genes, knockdown of SRCAP
significantly inhibited the reactivation of some transcripts such as
EPM2AIP1 from up-regulated to non-responsive. Although the
majority of genes that were up-regulated by 5-Aza-CdR in NC
siRNA treated cells were still induced in SRCAP siRNA treated
cells, the reactivation levels were strikingly decreased (red circles).
The fold changes of the 44 genes induced by demethylation were
calculated in the inserted box plot, further showing the significant
effects of SRCAP knockdown (p,2610
216). To validate this
genome-wide analysis, we randomly selected four candidate genes
(CHFR, CTCFL, SYCP3 and EPM2AIP1) from the pool of 44 genes
and analyzed the expression changes (Figure S6A–S6C). The
reactivation levels of four methylated genes were significantly
suppressed by SRCAP knockdown. We then validated the histone
marks changes on the promoters of CHFR and SYCP3. We found
that SRCAP knockdown prevented H2A.Z deposition as well as
diminished gene reactivation, which was consistent with our results
from MLH1 and CDKN2A. To confirm that the H2A.Z insertion
was causing the observed effects, we knocked down p400, which is
a homolog of SWR1 and has been identified as another key player
in H2A.Z deposition [13]. We found that inhibiting p400 could
also reduce the reactivation of MLH1 and CDKN2A in RKO cells
(Figure S6D). In addition to knocking down the two catalytic
subunits of SRCAP and p400 complexes, inhibition of YL-1, the
binding partner of H2A.Z in the SRCAP complex [32–33], also
suppressed 5-Aza-CdR induced gene reactivation (Figure S6E)
and depletion of the 21 nucleosome (Figure S6F).
Our integrated study reveals that 5-Aza-CdR robustly reduces
global promoter DNA methylation levels, and subsequently
reactivates gene expression. Decreasing SRCAP expression
inhibits global gene reactivation but has no effect on DNA
methylation at promoter. However the maintenance of active gene
expression might not require highly enriched H2A.Z.
Discussion
Although recent studies have begun to explore the epigenetic
factors involved in the 5-Aza-CdR mediated demethylation
process [21,24], our study focuses on the dynamic changes in
chromatin architecture immediately after 5-Aza-CdR treatment
(Figure 6). We demonstrate that removing DNA methylation
rapidly induces H2A.Z incorporation, which confirms the
antagonistic relationship between H2A.Z and DNA methylation
observed in genome-scale studies of arabidopsis, human breast tissue
and tumorigenesis of a B-cell lymphoma model in mouse [34–36].
Although some reports show that loss of pie1 in Arabidopsis or
H2A.Z in mammals increases DNA methylation levels at gene
body regions [34,37], our data demonstrate that DNA methylation
levels at promoter regions are not affected by transiently inhibiting
H2A.Z insertion. Previous reports have showed positive correla-
tions between H2A.Z insertion and the expression of CDKN1A,
estrogen receptor target genes, muscle differentiation-specific
genes and PcG protein target genes in ES cells [11,13,33]. Our
genome-wide expression results demonstrate that SRCAP-medi-
ated H2A.Z deposition at promoter regions is necessary for
complete gene reactivation induced by DNA demethylation. We
show that inhibition of SRCAP-mediated H2A.Z insertion
prevents nucleosome depletion at the promoters of MLH1 and
CDKN2A after 5-Aza-CdR treatment. In addition, knockdown of
YL-1, the binding partner of H2A.Z in the SRCAP complex, also
reduces the CDKN2A gene reactivation and nucleosome depletion
around the TSS region that are induced by 5-Aza-CdR treatment.
Collectively, our data provides evidence for the hypothesis that
SRCAP/H2A.Z directly promotes transcription by reducing
nucleosome occupancy at promoter regions [38]. Nevertheless,
H2A.Z enrichment is necessary but not sufficient for gene
reactivation according to our data. As shown at the MYOD1
promoter, the modest enrichment of H2A.Z contributes to the
establishment of a ‘‘permissive’’ environment regardless of the
subsequent gene reactivation status. The reduction of M.CviPI
accessibility at the MYOD1 promoter after SRCAP knockdown
suggests that H2A.Z mediated nucleosome depletion is not the
consequence of gene expression and might be an early event in
transcription initiation. In addition, Hardy et al [15] showed that
H2A.Z was recruited to the promoter regions prior to pol II
binding. We observed pol II enrichment at the MLH1 promoter
but not at the MYOD1 promoter, though both promoters have
been remodeled structurally, which suggested the formation of
‘‘permissive’’ promoter regions might not require the presence of
pol II at an early stage.
Unlike H2A.Z, histone H3 acetylation occurs concomitantly
with gene expression, and is not required for establishing this early
‘‘permissive’’ promoter. Furthermore, the data from the SRCAP
knockdown experiments strongly indicate that H2A.Z incorpora-
tion, especially SRCAP mediated deposition, is independent of
H3K9/K14 acetylation. Functional studies of the Tip48/49
complex , which shares some components of the SRCAP complex,
showed that acetylation of H2A enhanced H2A.Z insertion [39].
However, a recently published report demonstrated that inhibiting
NF-Y, one of the proteins with highly similarity to core histones,
prevented H2A.Z deposition at promoter regions but had no
observable effect on histone H3K9/14 acetylation, indirectly
supporting our conclusions [40].
Similarly to the behavior of H2A.Z, H3K4me3 enriches at
promoters following demethylation, in agreement with the
reported mutually exclusive relationship between H3K4me3 and
DNA methylation [41]. Although many reports show that
H3K4me3 levels are correlated with gene expression status,
Thomson et al [42] demonstrated that artificially inserted
promoter-less DNA sequences containing unmethylated CpG sites
were sufficient to acquire H3K4me3. In our study, DNA
demethylation associated H3K4me3 enrichment creates a ‘‘per-
missive’’ promoter configuration; however, such a configuration is
not sufficient for gene activation. The presence of key transcription
factors is also necessary [29]. In yeast, Set1, an H3K4
methyltransferase, and H2A.Z have redundant functions in
preventing the spread of Sir-mediated silencing, indicating that
the presence of H3K4 methylation marks and H2A.Z are not
dependent on each other [43]. Interestingly, our results show that
the enrichment of H3K4me3 is not affected after inhibiting
SRCAP-mediated H2A.Z deposition and suggest that in mam-
malian cells the regulation of these histone marks might not
depend on each other. Therefore, it would be interesting to study
the specific effects of H3K4me3 on chromatin remodeling after
DNA demethylation in the future.
It has been reported that certain DNA sequences and the
binding of pol II or transcription factors influence nucleosome
occupancy by different mechanisms [44–45]. Recent reports have
shown that methylated DNA facilitates nucleosome assembly in
vitro, and reciprocally, stable nucleosomes contribute to the
establishment and maintenance of DNA methylation [46–48].
Here, we apply the now well-established NOMe-seq assay to
investigate the correlation between nucleosome positioning and
DNA methylation after drug treatment [45,49]. Our data
demonstrate that promoter regions are highly occupied by
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methylated or hemimethylated in living cells, suggesting the
dominant role of DNA methylation in maintaining stable
nucleosomes. Using reconstituted histone octamers and single-
stranded M13 constructs, Deobagkar et al show that hemi-
methylated DNA prevents chromatin expression [50]. Thus
complete nucleosome depletion takes place only on symmetri-
cally demethylated DNA after 5-Aza-CdR treatment, which is
probably required for full gene activation. Furthermore, our
data have confirmed the feasibility of utilizing NOMe-seq in
future to investigate the drug induced nucleosome remodeling
globally.
According to our genome-wide analysis, 5-Aza-CdR induces
global demethylation yet only a limited number of genes are
significantly reactivated, indicating that CpG demethylation and
the subsequent establishment of open chromatin architectures are
essential but not sufficient to induce gene reactivation. The
‘‘permissive’’ promoters created by 5-Aza-CdR treatment, such as
the MYOD1 promoter, have active histone marks and NDRs,
which are needed for assembling of the transcriptional machinery,
but other regulatory factors are required to fully reactivate these
genes. Therefore, epigenetic modulators which regulate histone
marks and nucleosome positioning have strong abilities to promote
or impede the pharmacological functions of 5-Aza-CdR. Our
results provide a rationale to design clinical trials combining
DNMT inhibitors with other anticancer drugs, especially histone
deacetylase inhibitors, which facilitate histone acetylation. A
comprehensive understanding of the coordinated interplay
between epigenetic regulators and 5-Aza-CdR will help explain




RKO, a colon cancer cell line, was purchased from ATCC and
was maintained in MEM medium with 10% FBS. LD419, a
normal human bladder fibroblasts was generated by Dr Louis
Dubeau and was maintained in McCoy’s 5A supplemented with
20% FBS.
5-Aza-CdR treatment and transfection
RKO cells were plated at 2610
6 cells/100-mm dish and treated
with 1 mM of 5-Aza-CdR (Sigma Chemical Co., St. Louis, MO)
for 24 hours. The NC pool siRNA (D-001810-10-05) and the ON-
TARGET plus siRNA targeting SRCAP (L-004830-00-0005),
p400 (L-021272-01-0005) and YL-1 (VPS72 L-020097-00-0005)
(Thermo Fisher Scientific Inc.) were transfected into RKO cells
Figure 6. Simplified schematic of 5-Aza-CdR–induced DNA demethylation and chromatin configuration changes. During DNA
replication, 5-Aza-CdR is incorporated into DNA, sequesters DNMTs immediately and this results in demethylation. After a cycle of cell doubling, the
majority of DNA molecules are hemimethylated and occupied by nucleosomes. Subsequent DNA replications produce more symmetrically
demethylated DNA molecules, possessing NDRs around the TSS. In addition, DNA demethylation results in SRCAP-mediated H2A.Z deposition at
gene promoter, which promote gene reactivation.
doi:10.1371/journal.pgen.1002604.g006
Gene Reactivation Requires H2A.Z
PLoS Genetics | www.plosgenetics.org 9 March 2012 | Volume 8 | Issue 3 | e100260424 hours before 5-Aza-CdR treatment using DharmaFECT
TM
siRNA transfection reagents (Thermo Fisher Scientific Inc.).
Real-time RT–PCR
Total RNA was extracted using RNeasy kit (Qiagen) and was
converted to cDNA by M-MLV Reverse Transcriptase (Promega)
using random primer (Promega). The sequences of gene specific
primers and taqman-probs are available upon request. With each
set of PCR primers, titrations of known amounts of DNA were
included as a standard for quantization.
Methylation-sensitive single-nucleotide primer extension
(Ms-SNuPE)
DNA methylation level was determined by Ms-SNuPE as
described previously [51]. Briefly, CpG sites were interrogated for
each promoter. The methylation level of each gene is the average
of the three CpG sites examined by Ms-SNuPE.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described previously [52]. Ten mg of the
following antibodies were used: anti-Histone H3 (Abcam), anti-
acetylated Histone H3K9/14 (Milipore), anti-H2A.Z (Abcam) and
anti-RNA polymerase II(Abcam). Five ml of anti-H3K4me3
(Active Motif) antibody was used. Ten mg of Rabbit IgG
(Millipore) was used as a non-specific antibody control. PCR
primers are available upon request.
Nucleosome occupancy methylome-sequencing (NOMe-
seq)
Nuclei preparation and GpC Methyltransferase treatment were
performed as described previously [26]. Briefly, freshly extracted
nuclei were treated with 200 U of GpC methyltransferase for
15 min at 37uC. An equal volume of stopping solution (20 nM
Tris-HCl, 600 mM NaCl, 1% SDS, 10 mM EDTA) was added to
stop the reaction. The final mixture was incubated at 55uC
overnight with 400 mg/ml proteinase K. DNA was isolated and
bisulfite converted. The regions of interest were amplified and
cloned into pCR 2.1-TOPO vector (Invitrogen) for DNA
sequencing.
Hemimethylation assay
Hemimethylation analysis was performed as described previ-
ously. Undigested or Hpa II-digested DNA from RKO cells before
and after treatment was subjected to bisulfite modification. Hpa II
digests unmethylated DNA but does not cut a fully or
hemimethylated configuration of its CCGG target sequence.
Bisulfite-treated DNA was then amplified by PCR using Ms-
SNuPE primers that flanked one Hpa II site at the CDKN2A
promoter. The equations used to determine hemimethylation
levels used were as described previously [25].
Illumina Infinium DNA methylation assay
(HumanMethylation27 BeadChip)
The Illumina Infinium DNA methylation assay technology has
been described previously [30]. The Infinium DNA methylation
assay was performed at the USC Epigenome Center according to
the manufacturer’s specifications (Illumina, San Diego, CA). The
Illumina Infinium DNA methylation assay (HumanMethyla-
tion27_270596_v.1.2) examines DNA methylation status of
27,578 CpG sites located at promoter regions of 14,495 protein-
coding genes and 110 microRNAs. Downstream processing and
beta value calculations were done as previously described [53].
Gene expression assay (Illumina HumanWG-6 v3.0
Expression BeadChip)
Expression analysis was performed using the Illumina whole-
genome expression BeadChip (HumanWG-6 v3.0, 48,803 tran-
scripts) (Illumina). The hybridized chips were stained and scanned
using the Illumina HD BeadArray scanner (Illumina). Scanned
image and bead-level data processing were performed using the
BeadStudio 3.0.1 software (Illumina). The summarized data for
each bead type were then processed using the lumi package in
Bioconductor [54]. The data were log2 transformed and
normalized using Robust Spline Normalization (RSN) as imple-
mented in the lumi package.
Statistic analysis
All statistical tests were done using R software (R version 2.12.1,
2010-12-16, R Development Core Team, 2009). ‘lumi’ package
was used to normalize and process gene expression data. ‘samr’
(version 1.28) package was used for all permutation tests to access
significance of gene expression changes. Differential gene
expression (significance) change was established for each applica-
tion by setting the cut-off on a FDR of q=0.05 after applying
1000 permutation. The following CRAN packages were used to
generate plots: ‘ggplot2’ and ‘LSD’ (version 1.0). The H2A.Z ChIP
results from three biological experiments were analyzed by one
way ANOVA using Prism 3(GraphPad).
Accession numbers
All summarized probe profile data and processed expression
data and DNA methylation data which are used in this study have
been deposited to Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/projects/geo/) under accession Number GSE26685.
Supporting Information
Figure S1 5-Aza-CdR treatment produces asymmetrically
methylated DNA duplexes. A. ChIP results of RNA pol II
enrichment at the indicated time points after 5-Aza-CdR
treatment are shown. B. The schematic of working mechanism
of hemimethylation assay. (U), unmethylated DNA; (H), hemi-
methylated DNA; (F), fully methylated DNA. Arrows indicate the
Ms-SNuPE PCR primers. Open and filled circles represent
unmethylated and methylated CpG sites. C. Levels of hemi-
methylated (H), fully methylated (F), and unmethylated (U) DNA
at the Hpa II site of the CDKN2A promoter after 5-Aza-CdR
treatment are shown. Values are expressed as relative percentages;
error bars, the SD of three independent determinations. D.
Agarose gel pictures showing the PCR amplicons for Hemi-
methylation assay. Msp I treated DNA was used as control
showing the efficiency of enzyme digestion.
(TIF)
Figure S2 The CpG methylation status of the specifically
amplified demethylated DNA single strands Arrows indicate TSSs
and the upper vertical bars represent CpG sites. Open and filled
circles represent unmethylated and methylated CpG sites
respectively. Data represent the CpG methylation status of the
DNA single strands shown in Figure 3.
(TIF)
Figure S3 SRCAP mediated H2A.Z deposition has minimal
effects on constitutively active genes. A. RT-PCR results of the
SRCAP mRNA levels in RKO cells show the knockdown
efficiency of siRNA treatments. B. The methylation levels at the
MLH1, CDKN2A and MYOD1 promoters after SRCAP knock-
down were measured by Ms-SNuPE in RKO cells. Error bars
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results show the nucleosome occupancy levels at the GRP78
promoters after the indicated treatments in RKO cells. D, E. The
gene expression levels of LAMB3 and G3BP in RKO cells were
measured by RT-PCR. The data represent the means of biological
triplicates. The enrichments of histone marks after SRCAP
knockdown were measured by ChIP and normalized to Histone
H3 levels. The data represent biological duplicates. F, G NOMe-
seq results show the nucleosome occupancy at the LAMB3 and
G3BP promoters after SRCAP knockdown in RKO cells.
(TIF)
Figure S4 The expression levels and chromatin configurations of
constitutively active genes are not disrupted by SRCAP knock-
down in LD419 cells. A. The mRNA levels of the indicated genes
after SRCAP knockdown in LD419 cells were measured by RT-
PCR. Seventy-two hours after SRCAP siRNA treatment, the
enrichments of the histone marks at MLH1 and CDKN2A
promoters were investigated by ChIP. Error bars represent the
range between technical duplicates. B. The nucleosome occupancy
at the MLH1 promoter was detected by NOMe-seq in LD419 cells
treated with the indicated siRNA for 72 hours.
(TIF)
Figure S5 DNA methylation and gene expression changes
globally after 5-Aza-CdR treatment and SRCAP knockdown.
A,B. Scatter plot over-layed with histogram and density distribu-
tion. Each dot represents an interrogated CpG probes beta value.
Colored dots represents density or number of probes as indicated
in the adjacent axis as illustrated as a both a histogram and density
distribution. Contour lines are drawn to further illustrate the
number of probes for a specified region. A. Represents a scatter
plot between 5-Aza-CdR vs PBS treatment (control) in SRCAP
siRNA treated RKO cells. B. Represents a scatter plot between
SRCAP siRNA vs NC siRNA treated cells after 5-Aza-CdR
treatment. C, D. Permutation results showing the number of
transcripts significantly expressed as determined by the delta-
cutoff. Results are presented as a Q-Q plot. C. analysis between 5-
Aza-CdR vs PBS in NC siRNA treated cells. D. analysis between
5-Aza-CdR vs PBS in SRCAP siRNA treated cells. E. The gene
expression log2 fold difference is plotted on the x-axis, and the q-
value which accesses significance is plotted on the y-axis (21*
log10 scale). Probes that are identified as significantly different
between two groups are colored in red. (5-Aza-CdR vs PBS in
SRCAP siRNA treated cells) F. Venn diagram showing the
number of differentially expressed genes (or transcripts) overlap-
ping each pair of analysis.
(TIF)
Figure S6 H2A.Z is required for 5-Aza-CdR induced gene re-
expression. A, B, C. The mRNA levels of the indicated genes were
measured by RT-PCR to validate the genome-wide expression
array results. The enrichments of histone marks at CHFR and
SYCP3promoter were measured by ChIP and normalized to
Histone H3 levels after the indicated treatment. The data
represent biological duplicates. D, E. RKO cells were treated as
indicated, and the mRNA levels of the indicated genes detected by
RT-PCR as shown. Error bars represent the range between
technical duplicates. F. NOMe-seq results show the nucleosome
occupancy at the CDKN2A promoter after the indicated treatment.
Green bars presents regions of 250 bp in length, which covers the
21 nucleosome plus 100 bp downstream of that nucleosome.
(TIF)
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